DE69842060D1 - Verfahren zur Gewinnung aktivierter T-Zellen und mit Antigen-inkubierten Antigen-präsentierender Zellen - Google Patents

Verfahren zur Gewinnung aktivierter T-Zellen und mit Antigen-inkubierten Antigen-präsentierender Zellen

Info

Publication number
DE69842060D1
DE69842060D1 DE69842060T DE69842060T DE69842060D1 DE 69842060 D1 DE69842060 D1 DE 69842060D1 DE 69842060 T DE69842060 T DE 69842060T DE 69842060 T DE69842060 T DE 69842060T DE 69842060 D1 DE69842060 D1 DE 69842060D1
Authority
DE
Germany
Prior art keywords
antigen
cells
activated
pbls
loaded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69842060T
Other languages
English (en)
Inventor
Babita Agrawal
Mark J Krantz
Mark A Reddish
Michael B Longenecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cascadian Therapeutics Inc
Original Assignee
Oncothyreon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncothyreon Inc filed Critical Oncothyreon Inc
Application granted granted Critical
Publication of DE69842060D1 publication Critical patent/DE69842060D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/46447—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69842060T 1997-05-08 1998-05-07 Verfahren zur Gewinnung aktivierter T-Zellen und mit Antigen-inkubierten Antigen-präsentierender Zellen Expired - Lifetime DE69842060D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4594997P 1997-05-08 1997-05-08

Publications (1)

Publication Number Publication Date
DE69842060D1 true DE69842060D1 (de) 2011-01-27

Family

ID=21940709

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69842060T Expired - Lifetime DE69842060D1 (de) 1997-05-08 1998-05-07 Verfahren zur Gewinnung aktivierter T-Zellen und mit Antigen-inkubierten Antigen-präsentierender Zellen
DE69839443T Expired - Lifetime DE69839443D1 (de) 1997-05-08 1998-05-07 Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69839443T Expired - Lifetime DE69839443D1 (de) 1997-05-08 1998-05-07 Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen

Country Status (10)

Country Link
US (1) US6600012B1 (de)
EP (3) EP1634949B1 (de)
JP (1) JP4480800B2 (de)
AT (2) ATE394474T1 (de)
AU (1) AU727863B2 (de)
CA (1) CA2289742C (de)
DE (2) DE69842060D1 (de)
DK (1) DK1634949T3 (de)
ES (1) ES2357960T3 (de)
WO (1) WO1998050527A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906744A1 (de) * 1999-02-18 2000-08-24 Martin Roecken Verfahren zur Herstellung antitumoraler Th1-Zellen
EP1171612A2 (de) * 1999-04-09 2002-01-16 Biomira, Inc. Telomerase-spezifisches krebsimpfstoff
DE19917195B4 (de) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
EP1210430B1 (de) * 1999-09-08 2006-08-30 Transgene S.A. Von MUC-1 abgeleitete Peptide
GB9921337D0 (en) * 1999-09-09 1999-11-10 Axis Genetics Plc Modified plant viruses
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
ES2424131T3 (es) * 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
WO2003077865A2 (en) 2002-03-15 2003-09-25 Baxter International Inc. Methods and compositions for directing cells to target organs
WO2003089574A2 (en) * 2002-04-15 2003-10-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
WO2004022590A2 (en) * 2002-09-05 2004-03-18 Cell Center Cologne Gmbh Immunogenic muc1 glycopeptides
BR0314471A (pt) * 2002-10-10 2005-08-02 Us Dept Veterans Affairs Detecção, localização e estadiamento de tumores usando linfócitos ativados classificados dirigidos a um epitopo especìfico do tumor
US20050045205A1 (en) * 2003-08-29 2005-03-03 Stach Steven R. Apparatus and method for cleaning printed circuit boards
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
WO2005058937A2 (en) * 2003-12-12 2005-06-30 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
TWI395591B (zh) 2004-04-01 2013-05-11 Oncothyreon Inc 黏液性糖蛋白（ｍｕｃ-１）疫苗
US20080267963A1 (en) * 2004-11-02 2008-10-30 Biomedical Research Model, Inc. Methods of Cancer Treatment/Prevention Using Cancer Cell-Specific Surface Antigens
BRPI0613510A2 (pt) * 2005-06-28 2011-01-11 Biomira Inc processo de tratamento de pacientes com uma vacina de glicoproteìna mucinosa (muc-1)
CA2658227A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
US20120039984A1 (en) 2008-07-03 2012-02-16 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
WO2010030505A1 (en) * 2008-09-10 2010-03-18 Austin American Technology Corporation Cleaning and testing ionic cleanliness of electronic assemblies
US9597392B2 (en) 2010-05-10 2017-03-21 Ascend Biopharmaceuticals Pty Ltd. Use of high molecular weight mannan for inducing and/or enhancing an immune response
US8889616B2 (en) 2011-02-24 2014-11-18 Oncothyreon Inc. MUC1 based glycolipopeptide vaccine with adjuvant
DK2800762T3 (en) 2012-01-03 2018-04-16 Us Health NATIVE AND AGONISTIC CTL EPITOPES OF THE MUC1 TUMOR ANTIGEN
KR20160007640A (ko) 2013-05-14 2016-01-20 메르크 파텐트 게엠베하 Muc-1 리포펩티드를 이용한 백신접종에 의한 폐암의 치료 방법
WO2015058831A1 (en) 2013-10-25 2015-04-30 Merck Patent Gmbh Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines
IL297617B2 (en) 2016-12-22 2023-11-01 Cue Biopharma Inc Multimeric polypeptides modulate T cells and methods for their use
EP3565829A4 (de) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-zell-modulierende multimere polypeptide und verfahren zur verwendung davon
KR102619015B1 (ko) 2017-03-15 2023-12-28 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
EP3986448A4 (de) * 2019-06-19 2023-07-12 Cue Biopharma, Inc. Multimere t-zell-modulierende polypeptide und verfahren zur verwendung davon
JP2023526723A (ja) 2020-05-12 2023-06-23 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034628A1 (en) 1994-06-13 1995-12-21 Unilever N.V. Bleach activation
CA2192655A1 (en) * 1994-06-14 1995-12-21 Edgar G. Engleman Methods for in vivo t cell activation by antigen-pulsed dendritic cells
WO1996022067A2 (en) * 1994-12-27 1996-07-25 United Biomedical, Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics
US6168804B1 (en) * 1995-06-07 2001-01-02 University Of Alberta Method for eliciting Th1-specific immune response
CA2282300C (en) 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen

Also Published As

Publication number Publication date
CA2289742C (en) 2013-07-16
DE69839443D1 (de) 2008-06-19
EP0986636A1 (de) 2000-03-22
WO1998050527A1 (en) 1998-11-12
EP1634949A1 (de) 2006-03-15
CA2289742A1 (en) 1998-11-12
ES2357960T3 (es) 2011-05-04
EP1634949B1 (de) 2010-12-15
DK1634949T3 (da) 2011-03-28
EP0986636B1 (de) 2008-05-07
JP4480800B2 (ja) 2010-06-16
JP2001525668A (ja) 2001-12-11
EP2341072A3 (de) 2013-10-30
ATE394474T1 (de) 2008-05-15
US6600012B1 (en) 2003-07-29
EP2341072A2 (de) 2011-07-06
AU727863B2 (en) 2001-01-04
ATE491465T1 (de) 2011-01-15
AU7371298A (en) 1998-11-27

Similar Documents

Publication Publication Date Title
DE69842060D1 (de) Verfahren zur Gewinnung aktivierter T-Zellen und mit Antigen-inkubierten Antigen-präsentierender Zellen
ATE330002T1 (de) Verfahren zur herstellung von membranvesikeln
ID22689A (id) Metode untuk mengaktifkan sel-sel yang menunjukan-sifat antigen manusia, sel-sel teraktifkan yang menunjukan sifat antigen manusia, dan penggunaannya
HK1087335A1 (en) Survivin-derived peptides and use thereof
ATE116329T1 (de) Zellenfreier t-zellenantigenrezeptor und klinische verwendung.
EP1249490A3 (de) In vitro Aktivierung von cytotoxischen T Zellen
PL374326A1 (en) Microoroganisms and cells for diagnosis and therapy of tumors
HUP0103598A2 (hu) Készítmények és eljárások WT1-specifikus immunterápiás alkalmazásra
ES2177964T3 (es) Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.
EP2016930A3 (de) Zelltherapieverfahren zur Behandlung von Tumoren
RS20100249A (en) CONJUGATES AND PROCEDURES FOR THEIR PRODUCTION, AND THEIR USE FOR THE TRANSPORT OF MOLECULES THROUGH BIOLOGICAL MEMBRANE
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
ATE321843T1 (de) Zellen, kulturverfahren, und ihre verwendung in autologer transplantationstherapie
ATE514780T1 (de) Zusammensetzungen für die therapie und diagnose von brustkrebs und verwendung davon
DE3677848D1 (de) Chromosomale dna-sequenz, expressionsvektor fuer menschlichen gewebeplasminogen aktivierenden faktor mit diesem transfektierte, gezuechtete zellen, sowie verfahren zur herstellung des genannten aktivierungsfaktors.
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
RU2000122041A (ru) Способ лечения злокачественных опухолей головного мозга
ATE276364T1 (de) Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren
RU2170016C2 (ru) Способ насыщения трансплантатов костной губчатой ткани медикаментами
WO2000015767A3 (en) Antigen-presenting cells and their use in therapy
WO2005040409A3 (de) Verfahren zur diagnose rheumatoider erkrankungen und mittel hierfür